knock risk
baxter result guidanc rais quell concern specif
relat medic deliveri reduc headwind
macro tailwind esrd new product myxredlin
theranova spectrum increas confid
acceler teen ep growth
result beat expect baxter organ growth ex cyclo
manag guidanc estim reflect pt
momentum acceler segment result gener in-lin
model see exhibit except pharma vs mse
advanc surgeri vs mse partial driven
non-cor factor cyclo pharma competitor suppli disrupt
advanc surgeri see devic deriv gross margin
pt weaker estim base unfavor product mix mainli
compound servic pharma increment expens relat dialyz
manufactur bp despit oper margin bp
estim driven sg leverag ep beat estim
mainli driven oper margin improv vs mse tax
vs mse top-line beat off-set mix driven weaker gross
icat deliveri concern eas preview deliveri
perform investor focu prior commentari point lsd growth
impli sequenti improv revenu
beat estim impli pt momentum acceler
manag reiter segment guidanc perform
step right direct provid increment comfort
achiev year perform fulli de-risk
model impli pt momentum acceler howev
discuss deliveri perform critic full-year guidanc
repres largest quarter sequenti improv declin
respect sever factor leav us
comfort acceler includ gpo contract sign idn
win occur gpo contract sign inventori end-market stabil
recaptur initi ww infus system improv includ
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
spectrum iq pump traction us
acceler deck solid perform led baxter rais
organ growth guidanc ex cyclo growth
aid bp anniversari headwind brevibloc
hd contract exit alon path toward
growth next year becom clear addit discuss
pharma launch key driver acceler recent approv
myxredlin see reinforc thesi revenu
drive bp baxter growth renal propos reimburs
chang esrd discuss result multi-year tailwind
us busi well potenti reimburs chang theranova
drive addit upsid embed current estim acut
therapi baxter launch prismax discuss
potenti add bp growth bottom line baxter rais
ep guidanc midpoint follow
upsid quarter tailwind includ top-line guidanc rais
non-oper incom tax off-set
dialyz manufactur pressur
concern one timer simpli perform
due competit suppli disrupt partial non-cor pharma upsid
pharma cyclo drove pharma beat vs model
remain driven increas demand compound
servic strength also saw
floseal rais competitor disrupt potenti driver baxter
floseal see benefit materi
compani factor month addit benefit
suggest issu may persist clearli temporari tailwind
baxter focus expand surgeri disrupt hurt
floseal exampl help pull recothrom longer
competit issu persist share baxter could retain
margin gross margin declin bp y/i unfavor sale mix
mainli compound dialyz expens contribut bp
declin despit oper margin bp higher model
base sg leverag ep grew y/i long ago
investor question baxter abil grow earn doubl digit
updat guidanc assum midpoint
expand reimburs esrd treatment underappreci
recent discuss see expand dialysi reimburs
question get esrd reimburs expand reimburs
home dialysi clear posit baxter us renal busi commentari
around execut order implic call break new
ground though baxter announc plan invest support
initi mani year said believ put
lrp risk near-term manag discuss suppli chain
optim provid above-lrp save use
part fund invest current see baxter well posit
us pd market user-friendli autom pd platform amia
integr sharesourc telehealth platform final see
propos reimburs chang multi-year tailwind
compani revenu base us portion renal could drive segment growth
back baxter corpor target
path acceler becom clear remain overweight overweight
thesi baxter predic acceler drive multipl
expans above-p ep growth option capit deploy
guidanc rais organ growth increment posit step
toward top-line acceler remain underappreci
consensu remain confid path acceler
exit anniversari pump launch share recaptur pharma product
launch see emerg market growth discuss
addit detail ceo meet note upgrad note price
target base ebitda in-lin larg cap peer
acceler drive perform
acceler drive perform
price target reflect multipl
base case ebitda in-lin peer given lower wamgr
off-set margin expans opportun assum organ growth
margin reach
baxter margin ramp faster anticip assum compound-annual-growth-rate
back new product initi margin hit higher expect
guidanc om/gm ratio larg cap devic peer
baxter deploy capit wacc return diversifi
baxter achiev organ sale growth ex cyclo new
product geograph expans drive acceler margin continu
expand in-lin lrp goal baxter execut tuck-in medium size deal
also buy back stock
baxter new product initi fail deliv growth slow compound-annual-growth-rate
margin expans effort reliant upon benefit product mix fail
materi margin expans slow materi result oper
margin strateg action fail occur deliv wacc
baxter current multipl reflect
wamgr potenti
acceler medic deliveri
nutrit dynam stabil pipelin
baxter premium balanc sheet asset
risk low-return capit deploy
overst expect disciplin
approach involv repurchas
medic deliveri nutrit
headwind stabil contribut
low mid-singl digit growth come
growth leverag opportun
earn growth level includ
acceler
stabil medic deliveri
nutrit drive pt acceler vs
baxter expect new product sale
drive pt baxter
deploy balanc sheet
bp margin expans drive
pt earn
return growth medic deliveri
nutrit
next-gen pump platform launch share
risk achiev price
medic deliveri nutrit
recov expect
potenti activ below- wacc
inabl gener oper leverag
baxter struggl grow wamgr
million except ep
million
sale
sale
sale
sale
st def tax asset disposit
current matur lt debt leas oblig
commit conting
oper
incom disc op net tax
depreci amort
realiz excess tax benefit stock issu employ benefit plan
net period pension benefit opeb cost
sale discontinu oper
infus product-rel charg
loss gain relat conting payment liabil
chang balanc sheet item
oper
invest
acquisit invest net
divestitur invest activ
invest
financ
issuanc debt
payment oblig
increas decreas st debt
dividend common stock
proce realiz excess tax benefit stock issu employe benefit plan
purchas treasuri stock issuanc equiti
financ
effect exchang rate chang
begin period balanc
end period balanc
